查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954633

全球女性性功能障碍 (FSD) 治疗市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的分析以及未来预测 (2026-2034)

Female Sexual Dysfunction Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 131 Pages | 商品交期: 请询问到货日

价格

女性性功能障碍 (FSD) 治疗市场成长驱动因素

2025 年全球女性性功能障碍 (FSD) 治疗市场规模为 5.3719 亿美元，预计将从 2026 年的 5.9574 亿美元增长至 2034 年的 16.5508 亿美元，预测期内复合年增长率高达 13.62%。北美地区在 2025 年占市场主导地位，市占率高达 88.90%，这得益于较高的认知度、较高的处方率和强劲的研发投入。预计到 2032 年，美国市场规模将达到 7.823 亿美元，反映出持续的创新和疗法的普及。

女性性功能障碍是指与性慾、性唤起、性反应或疼痛相关的持续性或復发性问题，这些问题会造成痛苦。由于雌激素水平下降，性交疼痛、性慾低下（HSDD）和生殖器-骨盆腔插入疼痛障碍（GPPPD）等症状在停经后女性中特别常见。此外，糖尿病、癌症和心血管疾病等慢性疾病会增加性功能障碍的风险，并推动对治疗的需求。

市场趋势

市场的一个关键趋势是越来越关注荷尔蒙疗法，特别是基于雌激素的疗法。局部雌激素疗法（LETs），如阴道乳膏、栓剂、胶囊和阴道环，被广泛用于治疗更年期症状，例如性交疼痛和阴道干涩。 预计到 2026 年，由于其疗效显着、价格合理且易于给药，雌激素疗法市场占有率将达到 59.36%。

製药公司正在扩大其雌激素产品组合，并在新的地区获得监管部门的批准。 Imvexxy 和 Osphena 等产品的销售成长凸显了阴道雌激素疗法的日益普及。此外，包括局部使用西地那非乳膏和其他非荷尔蒙疗法在内的创新疗法的临床试验正在进行中，从而拓展了治疗选择。

新冠疫情的影响

由于封锁、就医限制和药品供应减少，新冠疫情在 2020 年暂时阻碍了市场成长。处方量下降，Intrarosa 等关键产品的销售量在疫情期间大幅下滑。 然而，疫情后的復苏、远距医疗的扩展以及线上药局的普及，都促使治疗需求回升。数位健康领域的合作以及产品商业化的拓展等策略性举措，也为市场的稳定做出了贡献。

市场成长因素

研发投入增加

荷尔蒙疗法的潜在副作用推动了对更安全的非荷尔蒙疗法的需求。因此，製药公司正大力投资研发，以推出安全性更高的创新药物。产能的扩大和许可协议的签署，进一步提高了全球市场的产品供应。

疾病盛行率上升

性交疼痛和性功能障碍（HSDD）的盛行率在全球范围内不断上升，尤其是在停经后女性。研究表明，患有慢性疾病的女性性功能障碍的发生率更高。 女性性健康意识的提高和就医次数的增加促进了诊断和治疗率的上升，预计到2034年，市场规模将增长至16.5508亿美元。

限制因子

儘管市场成长潜力巨大，但认知度低仍是一个重大障碍。许多女性不了解性功能障碍及其治疗方案。社会偏见和不愿就医阻碍了相关疗法的进一步普及。此外，发展中地区对荷尔蒙疗法和非荷尔蒙疗法的认知度较低也限制了市场渗透率。 市场区隔分析 依药物分类 市场依药物可细分为氟班色林、布美拉诺肽、奥培米芬、雌激素疗法和其他疗法。预计到2026年，雌激素疗法将占主导地位，市占率高达59.36%，这主要归功于其在治疗更年期症状方面的高处方率。同时，由于临床研发活动的增加，预计非荷尔蒙疗法在预测期内将实现强劲成长。 依疾病分类 依疾病分类，市场包括性慾亢进症 (HSDD)、性交疼痛及其他疾病。性交疼痛细分市场在2026年占最大占有率，达到90.81%，这主要得益于其全球高发病率和日益增长的临床关注。由于人们对心理健康的认识不断提高，性慾亢进症细分市场预计将保持稳定成长。 依给药途径分类 市场依给药途径分为口服、注射及局部用药。注射给药途径在2026年占主导地位，市占率达70.70%，主要得益于其局部给药和减少全身副作用等优势。然而，由于产品不断创新，局部用药预计未来将获得更多关注。

依通路划分

预计到2026年，医院药局将占65.55%的市场。这主要得益于就诊量的增加以及处方药的便捷取得。零售药局和网路药局也因其便利性和与远距医疗的整合而迅速扩张。

区域洞察

预计到2025年，北美将以4.7739亿美元的市场规模引领市场，这得益于先进的医疗基础设施、较高的公众认知度以及产品审批。欧洲将占第二大市场占有率，这主要得益于积极的临床研究和监管措施。亚太地区预计将实现最高的复合年增长率，这主要得益于公众认知度的提高、老年女性人口的增长以及医疗服务可及性的改善。拉丁美洲和中东及非洲地区预计将实现温和成长，这主要得益于监管措施和疾病认知度的提高。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要疾病盛行率：依主要国家/地区划分（2025 年）
  • 在开发产品分析
  • 主要产业趋势：併购、业务合作
  • 新冠疫情对全球市场的影响

第五章 全球女性性功能障碍治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物分类
    • 氟班色林
    • 布雷梅拉诺肽
    • 奥斯培米芬
    • 雌激素疗法
    • 其他
  • 市场分析、洞察与预测：依疾病分类
    • 性慾亢进症 (HSDD)
    • 性交疼痛
    • 其他
  • 市场分析与洞察 • 预测：依给药途径分类
    • 口服
    • 肠外给药
    • 外用
  • 市场分析、洞察与预测：依分销管道分类
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析，洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美女性性功能障碍治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第七章 亚太地区女性性功能障碍治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚亚洲
    • 其他亚太地区

第八章 拉丁美洲女性性功能障碍治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第九章 中东与非洲女性性功能障碍治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

第十章 竞争分析

  • 全球市占率分析（2025）
  • 公司公司简介
    • Sprout Pharmaceuticals, Inc.
    • Mayne Pharma Group Limited
    • Duchesnay Pharmaceutical Group Inc.
    • PALATIN
    • Freya Pharma Solutions B.V.
    • Acerus Pharmaceuticals Corporation
    • Millicent Pharma Ltd. (Endoceutics, Inc.)
    • Pfizer Inc.
Product Code: FBI100850

Growth Factors of female sexual dysfunction (FSD) treatment Market

The global female sexual dysfunction (FSD) treatment market was valued at USD 537.19 million in 2025 and is projected to grow from USD 595.74 million in 2026 to USD 1,655.08 million by 2034, registering a strong CAGR of 13.62% during the forecast period. North America dominated the market with an 88.90% share in 2025, driven by high awareness, strong prescription rates, and robust R&D investments. The U.S. market is projected to reach USD 782.3 million by 2032, reflecting continued innovation and treatment adoption.

Female sexual dysfunction refers to persistent or recurrent issues related to sexual desire, arousal, response, or pain that cause distress. Conditions such as dyspareunia, hypoactive sexual desire disorder (HSDD), and genito-pelvic penetration pain disorder (GPPPD) are particularly prevalent among post-menopausal women due to declining estrogen levels. Additionally, chronic illnesses such as diabetes, cancer, and cardiovascular diseases increase the likelihood of sexual dysfunction, thereby driving treatment demand.

Market Trends

A key trend in the market is the growing focus on hormonal therapies, particularly estrogen-based treatments. Local estrogen therapies (LET), including creams, vaginal tablets, capsules, and rings, are widely prescribed for menopausal symptoms such as dyspareunia and vaginal dryness. In 2026, the estrogen therapy segment accounted for 59.36% of the market share, owing to its effectiveness, affordability, and ease of administration.

Pharmaceutical companies are expanding their estrogen product portfolios and securing regulatory approvals in new regions. Increased sales of products such as Imvexxy and Osphena highlight the rising adoption of vaginal estrogen therapies. Additionally, ongoing clinical trials for innovative therapies, including topical sildenafil cream and other non-hormonal treatments, are expanding the treatment landscape.

COVID-19 Impact

The COVID-19 pandemic temporarily hindered market growth in 2020 due to lockdowns, restricted hospital visits, and reduced drug availability. Prescription volumes declined, and sales of key products such as Intrarosa dropped significantly during the pandemic. However, post-pandemic recovery, telehealth expansion, and improved access to online pharmacies restored treatment demand. Strategic initiatives such as digital health partnerships and expanded product commercialization helped stabilize the market.

Market Growth Drivers

Rising R&D Investments

The potential side effects associated with hormonal therapies have increased demand for safer, non-hormonal alternatives. As a result, pharmaceutical companies are investing heavily in research and development to introduce innovative drugs with improved safety profiles. Manufacturing expansions and licensing agreements are further strengthening product availability across global markets.

Increasing Disease Prevalence

The prevalence of dyspareunia and HSDD among women, especially post-menopausal populations, is rising globally. Studies indicate high rates of sexual dysfunction among women with chronic conditions. Growing awareness of women's sexual health and increased medical consultations are contributing to higher diagnosis and treatment rates, supporting the market's projected expansion to USD 1,655.08 million by 2034.

Restraining Factors

Despite growth prospects, low awareness remains a significant barrier. A large proportion of women are unaware of sexual dysfunction disorders or available treatments. Social stigma and reluctance to seek medical consultation further limit adoption. Additionally, limited awareness of hormonal and non-hormonal therapies in developing regions restricts market penetration.

Market Segmentation Analysis

By Drug

The market is segmented into flibanserin, bremelanotide, ospemifene, estrogen therapy, and others. The estrogen therapy segment dominated with 59.36% share in 2026, driven by high prescription rates for menopausal symptoms. Meanwhile, non-hormonal therapies are expected to witness strong growth during the forecast period due to increasing clinical development activities.

By Disease

Based on disease, the market includes HSDD, dyspareunia, and others. The dyspareunia segment held the largest share of 90.81% in 2026, attributed to its high global prevalence and increased clinical focus. The HSDD segment is projected to grow steadily due to rising awareness and psychological health considerations.

By Route of Administration

The market is categorized into oral, parenteral, and topical routes. The parenteral segment dominated with 70.70% share in 2026, owing to advantages such as localized drug delivery and reduced systemic side effects. However, topical therapies are expected to gain traction with ongoing product innovations.

By Distribution Channel

Hospital pharmacies accounted for 65.55% share in 2026, driven by increased hospital visits and strong availability of prescription therapies. Retail and online pharmacies are also expanding rapidly due to convenience and telehealth integration.

Regional Insights

North America led the market with USD 477.39 million in 2025, supported by advanced healthcare infrastructure, high awareness, and product approvals. Europe holds the second-largest share due to active clinical research and regulatory initiatives. Asia Pacific is projected to witness the highest CAGR, driven by rising awareness, growing elderly female populations, and improved healthcare access. Latin America and the Middle East & Africa are expected to grow moderately with increasing regulatory initiatives and disease awareness.

Competitive Landscape

The market is relatively consolidated, with major players such as Pfizer Inc., Duchesnay Pharmaceutical Group Inc., Mayne Pharma Group Limited, PALATIN, and Sprout Pharmaceuticals leading the industry. Strong product portfolios, strategic partnerships, and licensing agreements are key competitive strategies.

Conclusion

The global female sexual dysfunction treatment market is poised for substantial growth, increasing from USD 537.19 million in 2025 to USD 595.74 million in 2026, and projected to reach USD 1,655.08 million by 2034 at a CAGR of 13.62%. Rising disease prevalence, strong R&D investments, growing awareness of women's sexual health, and expanded telehealth services are key drivers. Despite challenges such as low awareness and social stigma, continuous innovation and regulatory advancements are expected to support sustained long-term market expansion worldwide.

Growth Rate CAGR of 13.62% from 2026-2034

Segmentation By Drug

  • Flibanserin
  • Bremelanotide
  • Ospemifene
  • Estrogen Therapy
  • Others

By Disease

  • Hypoactive Sexual Desire Disorder (HSDD)
  • Dyspareunia
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug, Disease, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Drug, Disease, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Drug, Disease, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases - by Key Countries/Sub-regions, 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Impact of COVID-19 on the Global Market

5. Global Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Flibanserin
    • 5.1.2. Bremelanotide
    • 5.1.3. Ospemifene
    • 5.1.4. Estrogen Therapy
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease
    • 5.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 5.2.2. Dyspareunia
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East and Africa

6. North America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Flibanserin
    • 6.1.2. Bremelanotide
    • 6.1.3. Ospemifene
    • 6.1.4. Estrogen Therapy
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease
    • 6.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 6.2.2. Dyspareunia
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.5.1. U.K.
    • 6.5.2. Germany
    • 6.5.3. France
    • 6.5.4. Spain
    • 6.5.5. Italy
    • 6.5.6. Rest of Europe

7. Asia Pacific Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Flibanserin
    • 7.1.2. Bremelanotide
    • 7.1.3. Ospemifene
    • 7.1.4. Estrogen Therapy
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease
    • 7.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 7.2.2. Dyspareunia
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. Japan
    • 7.5.2. China
    • 7.5.3. India
    • 7.5.4. Australia
    • 7.5.5. Southeast Asia
    • 7.5.6. Rest of Asia Pacific

8. Latin America Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Flibanserin
    • 8.1.2. Bremelanotide
    • 8.1.3. Ospemifene
    • 8.1.4. Estrogen Therapy
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease
    • 8.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 8.2.2. Dyspareunia
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America

9. Middle East & Africa Female Sexual Dysfunction Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Flibanserin
    • 9.1.2. Bremelanotide
    • 9.1.3. Ospemifene
    • 9.1.4. Estrogen Therapy
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease
    • 9.2.1. Hypoactive Sexual Desire Disorder (HSDD)
    • 9.2.2. Dyspareunia
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. GCC
    • 9.5.2. South Africa
    • 9.5.3. Rest of Middle East & Africa

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Sprout Pharmaceuticals, Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. financials (Based on Availability)
    • 10.2.2. Mayne Pharma Group Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. financials (Based on Availability)
    • 10.2.3. Duchesnay Pharmaceutical Group Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. financials (Based on Availability)
    • 10.2.4. PALATIN
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. financials (Based on Availability)
    • 10.2.5. Freya Pharma Solutions B.V.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. financials (Based on Availability)
    • 10.2.6. Acerus Pharmaceuticals Corporation
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. financials (Based on Availability)
    • 10.2.7. Millicent Pharma Ltd. (Endoceutics, Inc.)
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. financials (Based on Availability)
    • 10.2.8. Pfizer Inc.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. financials (Based on Availability)

List of Tables

  • Table 01: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 02: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 03: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 04: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 05: Global Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Region, 2021-2034
  • Table 06: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 07: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 08: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 09: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 11: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 12: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 13: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 14: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 15: Europe Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 16: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 17: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 18: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 19: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Country/Sub-region, 2021-2034
  • Table 21: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 22: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Disease, 2021-2034
  • Table 23: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 24: Rest of the World Female Sexual Dysfunction Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Female Sexual Dysfunction Treatment Market Revenue Breakdown (USD million, %) by Region, 2026 & 2034
  • Figure 02: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Drug, 2026 & 2034
  • Figure 03: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Disease, 2026 & 2034
  • Figure 04: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Route of Administration, 2026 & 2034
  • Figure 05: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 06: Global Female Sexual Dysfunction Treatment Market Value Share (%), By Region, 2026 & 2034
  • Figure 07: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 08: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 09: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 10: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 11: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 12: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 16: North America Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 17: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 18: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 19: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 20: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 21: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 26: Europe Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 27: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 28: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 29: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 30: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 31: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Female Sexual Dysfunction Treatment Market Value (USD million), by Country/Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Female Sexual Dysfunction Treatment Market Value Share (%), by Country/Sub-region, 2025
  • Figure 37: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Drug, 2026 & 2034
  • Figure 38: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Drug, 2025
  • Figure 39: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Disease, 2026 & 2034
  • Figure 40: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Disease, 2025
  • Figure 41: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Route of Administration, 2026 & 2034
  • Figure 42: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Rest of the World Female Sexual Dysfunction Treatment Market Value (USD million), by Distribution Channel, 2026 & 2034
  • Figure 44: Rest of the World Female Sexual Dysfunction Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Global Female Sexual Dysfunction Treatment Market Share (%), By Company, 2025